Overview

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Study hypothesis: Treatment with dasatinib 100 mg QD is safe and efficacious when given to patients with Ph+ ALL in the post SCT setting.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Treatments:
Dasatinib